Dosing and administration in an mh crisis7

Required supportive measures

In addition to treatment with RYANODEX®, institute the following supportive measures:

  • Discontinue use of MH-triggering anesthetic agents (eg, volatile anesthetic gases and succinylcholine)7
  • Manage metabolic acidosis7
  • Institute cooling as necessary7
  • Maintain adequate diuresis as needed7

Administering RYANODEX®7

Administer RYANODEX® by intravenous push at a minimum dose of 1 mg/kg. If the physiologic and metabolic abnormalities of MH continue, administer additional intravenous boluses up to the maximum cumulative dosage of 10 mg/kg.


Dosage in the event of MH relapse7

If the physiologic and metabolic abnormalities reappear, repeat RYANODEX® dosing by intravenous push starting with 1 mg/kg.*


Dosage for prevention of malignant hyperthermia7

The recommended prophylactic dose of RYANODEX® is 2.5 mg/kg administered intravenously over a period of at least 1 minute, starting approximately 75 minutes prior to surgery. Avoid agents that trigger MH.

Precautions should be taken when administering RYANODEX® preoperatively for the prevention of malignant hyperthermia, including monitoring vital signs, avoiding known triggering agents, and monitoring for early clinical and metabolic signs of malignant hyperthermia that may indicate additional treatment is needed.

If surgery is prolonged, administer additional individualized RYANODEX® doses during anesthesia and surgery.


Dosage for pediatric patients7

The recommended weight-based dose of RYANODEX® for pediatric patients in the treatment and prevention of MH is the same as for adults for these indications.7

*Malignant Hyperthermia Association of the United States (MHAUS) recommends initial and repeat treatment doses of 2.5 mg/kg.8


See how RYANODEX® is designed for speed and efficiency in an MH crisis.


This is an MH case simulation. It shows real medical professionals following a real MH protocol. It’s a unique opportunity to watch the same MH crisis occur with different formulations.

Indication and Important Safety Information

VIEW ALL